Clinical Trial Update: Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Open-label Phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of GSK1120212 (trametinib) in subjects with solid tumors or lymphoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• GSK1120212 (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Solid Tumours | Phase 1 | Status: COMPLETED